Clinical trial to assess tolerability and subrogate efficacy effects of an abbreviated schedule with house dust mites mixture subcutaneous immunotherapy
I. Antépara1, A. Roger2, N. Bernedo3, R. Lleonart4, F. Rodríguez5, B. Madariaga6,
J. A. Asturias6, L. Begoña6, A. Martínez6, A. Landeta6, M. C. Gómez-Fernández maricruz.gomez@roxall.es6
Show more: Authors information and Publication history1Department of Allergology, Hospital Universitario de Basurto, Bilbao, Spain
2Section of Allergology, Hospital Universitario Germans Trias Pujol, Badalona, Spain
3Department of Allergology, Hospital Universitario Araba, Vitoria, Spain
4Department of Allergology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
5Department of Allergology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
6Department of R&D, ROXALL Medicina España S.A., Zamudio, Spain
History:Published online: 22 February 2021
Accepted: 24 March 2020
Received: 20 January 2020
Doi10.23822/EurAnnACI.1764-1489.140Summary
Objective. To evaluate the tolerability and efficacy of
Dermatophagoides pteronyssinus/Dermatophagoidesfarinae mixture subcutaneous immunotherapy (SCIT).
Methods. Patientsreceived an abbreviated build-up schedule. The aims were: number, percentage, and severityof adverse reactions. Secondary outcomes included: changes in immunoglobulin titers and changes in dose-response skin prick tests.
Results. Out of 289 administrations, 17% elicitedany clinically relevant adverse reaction. Most of them were local reactions (LR) (9.4%) and the rest (7.6%) were systemic. Significant increases in sIgG and sIgG4 were detectedin serum samples. Cutaneous reactivity decreased significantly.
Conclusions. SCIT withhouse dust mites mixture of ROXALL Medicina España S.A. seems to have an acceptabletolerability profile, induces blocking IgG and decreases skin reactivity.
Key wordsHouse dust mites; DPT/DF mixture; subcutaneous immunotherapy; rhinoconjunctivitis; abbreviated schedule.
Cite article as:Antépara I, Roger A, Bernedo N, Lleonart R, Rodríguez F, Madariaga B, Asturias JA, Begoña L, Martínez A, Landeta A, Gómez-Fernández MC,Clinical trial to assess tolerability and subrogate efficacy effects of an abbreviated schedule with house dust mites mixture subcutaneous immunotherapy, Eur Ann Allergy Clin Immunol 2021;53(2):67-74. doi:10.23822/EurAnnACI.1764-1489.140.
FULL TEXT
